Trials / Completed
CompletedNCT05073120
Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 103 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This was a multinational, non-interventional, cross-sectional survey conducted among HCPs based in the EU/EEA who prescribe Piqray. The survey assessed the knowledge of HCPs prescribing Piqray in relation to the management of hyperglycemia in patients treated with Piqray.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Piqray Prescriber's/HCP guide for hyperglycemia | oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA were provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aimed to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia. |
Timeline
- Start date
- 2022-02-28
- Primary completion
- 2024-06-05
- Completion
- 2024-06-05
- First posted
- 2021-10-11
- Last updated
- 2025-06-03
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT05073120. Inclusion in this directory is not an endorsement.